A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

Introduction Psoriasis is a chronic inflammatory skin disease that negatively impacts the quality of life of patients and their families. However, the most commonly used decision-making tools in ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

Among the 140 patients with psoriasis, chronic plaque psoriasis was most prevalent (86.4%). Moderate to severe disease was seen most frequently, with a mean (SD) PASI score of 13.0 (9.3). Only 0.7% ...

In contrast to conventional risk algorithms [ASCVD Risk Equation, Framingham Risk Score (FRS), SCORE Chart] derived from general population data, our model achieves parameter optimization through ...

Specifically, the PASI-75 response rate was 31.4% for the 25-mg twice-daily dose cohort, 74.3% for those receiving a 50-mg dose twice a day and and 59.5% for the 100-mg daily dose group, compared ...

Of those on placebo, 4.4% met the PASI 90 score. Response rates continued to ramp up at week 24, when 74.1% of patients on icotrokinra had clear or almost clear skin and 64.9% achieved PASI 90.

A predictive model for the time to relapse for patients with psoriasis discontinuing biologics following remission may enable dermatologists to intervene before psoriasis relapse, according to ...